California State Teachers Retirement System Grows Stock Position in Axsome Therapeutics, Inc. $AXSM

Posted by Geri Gentry on Aug 6th, 2026

California State Teachers Retirement System increased its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 22.2% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 41,132 shares of the company’s stock after purchasing an additional 7,465 shares during the quarter. California State Teachers Retirement System’s holdings in Axsome Therapeutics were worth $6,952,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Axsome Therapeutics by 4.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,923 shares of the company’s stock valued at $2,557,000 after buying an additional 1,002 shares during the last quarter. Jones Financial Companies Lllp boosted its position in Axsome Therapeutics by 2,407.9% during the first quarter. Jones Financial Companies Lllp now owns 7,624 shares of the company’s stock worth $889,000 after acquiring an additional 7,320 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in Axsome Therapeutics by 38.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 301,718 shares of the company’s stock valued at $35,189,000 after acquiring an additional 84,151 shares during the last quarter. Caxton Associates LLP acquired a new stake in Axsome Therapeutics in the 1st quarter valued at about $307,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Axsome Therapeutics by 29.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 74,892 shares of the company’s stock worth $8,735,000 after purchasing an additional 17,250 shares in the last quarter. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Price Performance

Axsome Therapeutics stock opened at $212.85 on Thursday. The company’s 50 day simple moving average is $237.84 and its 200-day simple moving average is $203.67. The company has a market capitalization of $10.95 billion, a price-to-earnings ratio of -57.06 and a beta of 0.65. Axsome Therapeutics, Inc. has a 1 year low of $101.11 and a 1 year high of $260.19. The company has a debt-to-equity ratio of 2.27, a quick ratio of 1.32 and a current ratio of 1.39.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last issued its quarterly earnings data on Monday, May 4th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.41). Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%.The company had revenue of $191.20 million during the quarter, compared to analyst estimates of $191.10 million. The business’s quarterly revenue was up 57.4% on a year-over-year basis. As a group, equities research analysts expect that Axsome Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Insider Transactions at Axsome Therapeutics

In related news, Director Susan Mahony sold 300 shares of the stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $237.21, for a total transaction of $71,163.00. Following the transaction, the director owned 1,129 shares of the company’s stock, valued at approximately $267,810.09. This represents a 20.99% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Roger Jeffs sold 286 shares of the stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $246.18, for a total transaction of $70,407.48. Following the sale, the director directly owned 58,653 shares in the company, valued at $14,439,195.54. This represents a 0.49% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 151,102 shares of company stock worth $36,147,341. 20.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Piper Sandler reissued an “overweight” rating and set a $258.00 price objective on shares of Axsome Therapeutics in a research note on Monday, May 4th. Oppenheimer set a $280.00 price target on shares of Axsome Therapeutics in a research report on Monday, May 4th. Truist Financial raised shares of Axsome Therapeutics to a “strong-buy” rating in a report on Monday, June 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Axsome Therapeutics in a research note on Friday, July 17th. Finally, Zacks Research lowered shares of Axsome Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, July 20th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $265.55.

View Our Latest Report on AXSM

Axsome Therapeutics Company Profile

(Free Report)

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.